Another etanercept biosimilar approved for arthritic conditions

Wednesday, 14 Oct 2020

The biosimilar brand of etanercept Rymti, Etera has been approved by the TGA for use in conditions including rheumatoid arthritis, psoriatic arthritis and non-radiographic axial spondyloarthritis.

The TNF inhibitor, marketed by Lupin Australia is indicated for the treatment of RA, PsA, nr-AxSpa, ankylosing spondylitis, juvenile idiopathic arthritis and plaque psoriasis.

It is a biosimilar for Pfizer’s Enbrel, which has been available in Australia since 2005, and joins other biosimilars such as Brenzys and Erelzi.

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic